FY2024 Earnings Forecast for Valneva Issued By HC Wainwright

Valneva SE (NASDAQ:VALN) – Equities researchers at HC Wainwright dropped their FY2024 earnings per share estimates for Valneva in a report released on Thursday, January 23rd. HC Wainwright analyst E. White now forecasts that the company will post earnings of $0.13 per share for the year, down from their previous estimate of $0.15. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Valneva’s current full-year earnings is $0.15 per share. HC Wainwright also issued estimates for Valneva’s FY2025 earnings at ($1.29) EPS and FY2026 earnings at ($1.17) EPS.

Valneva Stock Down 1.0 %

NASDAQ VALN opened at $4.85 on Monday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The company has a market capitalization of $394.12 million, a P/E ratio of -37.31 and a beta of 1.93. Valneva has a 12 month low of $3.62 and a 12 month high of $9.50. The company’s 50 day simple moving average is $4.29 and its 200 day simple moving average is $5.74.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC raised its stake in Valneva SE (NASDAQ:VALN) by 33.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.